Moberg Pharma AB (FRA:MB8) Moat Score: 3/10 (As of Jul. 01, 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
59 GF Score
Price €0.80
GF Value €1.07
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Moat Score?

Moberg Pharma AB FRA:MB8 +0.50% 59 Moat Score is 3 as of Jul. 01, 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.07. The stock has 1 warning sign investors should review. Among 1,031 Drug Manufacturers companies, Moberg Pharma AB ranks better than 86.13% on this metric.

Moberg Pharma AB has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Moberg Pharma AB has No Moat: Moberg Pharma AB has very weak competitive advantages. It lacks market leadership, significant customer switching costs, and strong brand strength. Its intellectual property is not sufficient to establish a durable competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Moberg Pharma AB might have No Moat - Very weak/transient advantages.

Moberg Pharma AB  (FRA:MB8) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Moberg Pharma AB Moat Score Related Terms

FRA:MB8 vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moberg Pharma AB Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Moat Score distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Moat Score falls into.


FRA:MB8
59GF Score
Moberg Pharma AB FRA:MB8
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Moberg Pharma AB (FRA:MB8) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Moberg Pharma AB ranks #143 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Moberg Pharma AB's Moat Score too high?
Moberg Pharma AB's current Moat Score is 3. Based on the distribution chart, Moberg Pharma AB ranks #143 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #143 out of 1031 companies for Moat Score. This places Moberg Pharma AB in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Moberg Pharma AB's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Moat Score of 3. The stock's GF Value™ is €1.07, compared to a current price of €0.80 — trading 25.7% below its estimated fair value. The current Moat Score is 3. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.80 is trading 25.7% below its estimated GF Value™ of €1.07.

Key valuation signals for FRA:MB8:

  • Moat Score: 3
  • GF Value™: €1.07 vs. price of €0.80 (25.7% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for FRA:MB8

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€1.07
GF Value